Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K. Abou‐Alfa, Bruno Sangro, George Lau et al.|NEJM Evidence|2022Cited by 1.4k
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trialYelena Y. Janjigian, Sun Young Rha, Sara Lonardi et al.|The Lancet|2023Cited by 461